Loading…
Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers
Biliary tract cancer (BTC) is a heterogeneous group of rare gastrointestinal malignancies with dismal prognosis often associated with inflammation. We assessed the prognostic value of IL6 and YKL-40 compared with CA19-9 before and during palliative chemotherapy. We also investigated in mice whether...
Saved in:
| Published in: | Clinical cancer research 2020-11, Vol.26 (21), p.5655-5667 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c411t-7b4bbee7756696a72c3b4813864053be9092925b9d68fbcd307594af6f5d2a0f3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c411t-7b4bbee7756696a72c3b4813864053be9092925b9d68fbcd307594af6f5d2a0f3 |
| container_end_page | 5667 |
| container_issue | 21 |
| container_start_page | 5655 |
| container_title | Clinical cancer research |
| container_volume | 26 |
| creator | Høgdall, Dan O'Rourke, Colm J Dehlendorff, Christian Larsen, Ole F Jensen, Lars H Johansen, Astrid Z Dang, Hien Factor, Valentina M Grunnet, Mie Mau-Sørensen, Morten Oliveira, Douglas V N P Linnemann, Dorte Boisen, Mogens K Wang, Xin W Johansen, Julia S Andersen, Jesper B |
| description | Biliary tract cancer (BTC) is a heterogeneous group of rare gastrointestinal malignancies with dismal prognosis often associated with inflammation. We assessed the prognostic value of IL6 and YKL-40 compared with CA19-9 before and during palliative chemotherapy. We also investigated in mice whether IL6R inhibition in combination with gemcitabine could prolong chemosensitivity.
A total of 452 Danish participants with advanced (locally advanced and metastatic) BTC were included from six clinical trials (February 2004 to March 2017). Serum CA19-9, IL6, and YKL-40 were measured before and during palliative treatment. Associations between candidate biomarkers and progression-free survival (PFS) and overall survival (OS) were analyzed by univariate and multivariate Cox regression. Effects of inhibiting IL6R and YKL-40 were assessed
, and of IL6R inhibition
.
High pretreatment levels of CA19-9, IL6, and YKL-40, and increasing levels during treatment, were associated with short PFS and OS in patients with advanced BTC. IL6 provided independent prognostic information, independent of tumor location and in patients with normal serum CA19-9. ROC analyses showed that IL6 and YKL-40 were predictive of very short OS (OS < 6 months), whereas CA19-9 was best to predict OS > 1.5 years. Treatment with anti-IL6R and gemcitabine significantly diminished tumor growth when compared with gemcitabine monotherapy in an
transplant model of BTC.
Serum IL6 and YKL-40 are potential new prognostic biomarkers in BTC. IL6 provides independent prognostic information and may be superior to CA19-9 in certain contexts. Moreover, anti-IL6R should be considered as a new treatment option to sustain gemcitabine response in patients with BTC. |
| doi_str_mv | 10.1158/1078-0432.CCR-19-2700 |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8998158</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32933994</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-7b4bbee7756696a72c3b4813864053be9092925b9d68fbcd307594af6f5d2a0f3</originalsourceid><addsrcrecordid>eNpVkF1LwzAUhoMobk5_gpI_0JnvNDeClqmDgTLrpYQkTbfq1o6kE_bvbZkbepUDed73cB4ArjEaY8zTW4xkmiBGyTjL5glWCZEInYAh5lwmlAh-2s0HZgAuYvxECDOM2DkYUKIoVYoNwcebD9s1nM4ENBEa-BqaRd3EtnLwoWrWJnz5AE1d9MR8j-RLH8zGb3smN2HhW1jVHb2qTNjBPBjXwszUzod4Cc5Ks4r-6vcdgffHSZ49J7OXp2l2P0scw7hNpGXWei8lF0IJI4mjlqWYpoIhTq1XSBFFuFWFSEvrCookV8yUouQFMaikI3C3791s7doXztdtMCu9CVV3wU43ptL_f-pqqRfNt06VSjubXQHfF7jQxBh8ecxipHvfunepe5e6862x0r3vLnfzd_ExdRBMfwCnxHvm</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers</title><source>Freely Accessible Science Journals</source><creator>Høgdall, Dan ; O'Rourke, Colm J ; Dehlendorff, Christian ; Larsen, Ole F ; Jensen, Lars H ; Johansen, Astrid Z ; Dang, Hien ; Factor, Valentina M ; Grunnet, Mie ; Mau-Sørensen, Morten ; Oliveira, Douglas V N P ; Linnemann, Dorte ; Boisen, Mogens K ; Wang, Xin W ; Johansen, Julia S ; Andersen, Jesper B</creator><creatorcontrib>Høgdall, Dan ; O'Rourke, Colm J ; Dehlendorff, Christian ; Larsen, Ole F ; Jensen, Lars H ; Johansen, Astrid Z ; Dang, Hien ; Factor, Valentina M ; Grunnet, Mie ; Mau-Sørensen, Morten ; Oliveira, Douglas V N P ; Linnemann, Dorte ; Boisen, Mogens K ; Wang, Xin W ; Johansen, Julia S ; Andersen, Jesper B</creatorcontrib><description>Biliary tract cancer (BTC) is a heterogeneous group of rare gastrointestinal malignancies with dismal prognosis often associated with inflammation. We assessed the prognostic value of IL6 and YKL-40 compared with CA19-9 before and during palliative chemotherapy. We also investigated in mice whether IL6R inhibition in combination with gemcitabine could prolong chemosensitivity.
A total of 452 Danish participants with advanced (locally advanced and metastatic) BTC were included from six clinical trials (February 2004 to March 2017). Serum CA19-9, IL6, and YKL-40 were measured before and during palliative treatment. Associations between candidate biomarkers and progression-free survival (PFS) and overall survival (OS) were analyzed by univariate and multivariate Cox regression. Effects of inhibiting IL6R and YKL-40 were assessed
, and of IL6R inhibition
.
High pretreatment levels of CA19-9, IL6, and YKL-40, and increasing levels during treatment, were associated with short PFS and OS in patients with advanced BTC. IL6 provided independent prognostic information, independent of tumor location and in patients with normal serum CA19-9. ROC analyses showed that IL6 and YKL-40 were predictive of very short OS (OS < 6 months), whereas CA19-9 was best to predict OS > 1.5 years. Treatment with anti-IL6R and gemcitabine significantly diminished tumor growth when compared with gemcitabine monotherapy in an
transplant model of BTC.
Serum IL6 and YKL-40 are potential new prognostic biomarkers in BTC. IL6 provides independent prognostic information and may be superior to CA19-9 in certain contexts. Moreover, anti-IL6R should be considered as a new treatment option to sustain gemcitabine response in patients with BTC.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-19-2700</identifier><identifier>PMID: 32933994</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Animals ; Antigens, Tumor-Associated, Carbohydrate - blood ; Antigens, Tumor-Associated, Carbohydrate - genetics ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Biliary Tract Neoplasms - blood ; Biliary Tract Neoplasms - drug therapy ; Biliary Tract Neoplasms - genetics ; Biliary Tract Neoplasms - pathology ; Biomarkers, Tumor - blood ; Cell Proliferation - drug effects ; Chitinase-3-Like Protein 1 - blood ; Chitinase-3-Like Protein 1 - genetics ; Deoxycytidine - administration & dosage ; Deoxycytidine - adverse effects ; Deoxycytidine - analogs & derivatives ; Disease-Free Survival ; Female ; Humans ; Interleukin-6 - blood ; Interleukin-6 - genetics ; Male ; Mice ; Middle Aged ; Palliative Care ; Prognosis ; Progression-Free Survival ; Receptors, Interleukin-6 - antagonists & inhibitors ; Receptors, Interleukin-6 - blood ; Receptors, Interleukin-6 - genetics</subject><ispartof>Clinical cancer research, 2020-11, Vol.26 (21), p.5655-5667</ispartof><rights>2020 American Association for Cancer Research.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-7b4bbee7756696a72c3b4813864053be9092925b9d68fbcd307594af6f5d2a0f3</citedby><cites>FETCH-LOGICAL-c411t-7b4bbee7756696a72c3b4813864053be9092925b9d68fbcd307594af6f5d2a0f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,786,790,891,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32933994$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Høgdall, Dan</creatorcontrib><creatorcontrib>O'Rourke, Colm J</creatorcontrib><creatorcontrib>Dehlendorff, Christian</creatorcontrib><creatorcontrib>Larsen, Ole F</creatorcontrib><creatorcontrib>Jensen, Lars H</creatorcontrib><creatorcontrib>Johansen, Astrid Z</creatorcontrib><creatorcontrib>Dang, Hien</creatorcontrib><creatorcontrib>Factor, Valentina M</creatorcontrib><creatorcontrib>Grunnet, Mie</creatorcontrib><creatorcontrib>Mau-Sørensen, Morten</creatorcontrib><creatorcontrib>Oliveira, Douglas V N P</creatorcontrib><creatorcontrib>Linnemann, Dorte</creatorcontrib><creatorcontrib>Boisen, Mogens K</creatorcontrib><creatorcontrib>Wang, Xin W</creatorcontrib><creatorcontrib>Johansen, Julia S</creatorcontrib><creatorcontrib>Andersen, Jesper B</creatorcontrib><title>Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Biliary tract cancer (BTC) is a heterogeneous group of rare gastrointestinal malignancies with dismal prognosis often associated with inflammation. We assessed the prognostic value of IL6 and YKL-40 compared with CA19-9 before and during palliative chemotherapy. We also investigated in mice whether IL6R inhibition in combination with gemcitabine could prolong chemosensitivity.
A total of 452 Danish participants with advanced (locally advanced and metastatic) BTC were included from six clinical trials (February 2004 to March 2017). Serum CA19-9, IL6, and YKL-40 were measured before and during palliative treatment. Associations between candidate biomarkers and progression-free survival (PFS) and overall survival (OS) were analyzed by univariate and multivariate Cox regression. Effects of inhibiting IL6R and YKL-40 were assessed
, and of IL6R inhibition
.
High pretreatment levels of CA19-9, IL6, and YKL-40, and increasing levels during treatment, were associated with short PFS and OS in patients with advanced BTC. IL6 provided independent prognostic information, independent of tumor location and in patients with normal serum CA19-9. ROC analyses showed that IL6 and YKL-40 were predictive of very short OS (OS < 6 months), whereas CA19-9 was best to predict OS > 1.5 years. Treatment with anti-IL6R and gemcitabine significantly diminished tumor growth when compared with gemcitabine monotherapy in an
transplant model of BTC.
Serum IL6 and YKL-40 are potential new prognostic biomarkers in BTC. IL6 provides independent prognostic information and may be superior to CA19-9 in certain contexts. Moreover, anti-IL6R should be considered as a new treatment option to sustain gemcitabine response in patients with BTC.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Animals</subject><subject>Antigens, Tumor-Associated, Carbohydrate - blood</subject><subject>Antigens, Tumor-Associated, Carbohydrate - genetics</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Biliary Tract Neoplasms - blood</subject><subject>Biliary Tract Neoplasms - drug therapy</subject><subject>Biliary Tract Neoplasms - genetics</subject><subject>Biliary Tract Neoplasms - pathology</subject><subject>Biomarkers, Tumor - blood</subject><subject>Cell Proliferation - drug effects</subject><subject>Chitinase-3-Like Protein 1 - blood</subject><subject>Chitinase-3-Like Protein 1 - genetics</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - adverse effects</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Interleukin-6 - blood</subject><subject>Interleukin-6 - genetics</subject><subject>Male</subject><subject>Mice</subject><subject>Middle Aged</subject><subject>Palliative Care</subject><subject>Prognosis</subject><subject>Progression-Free Survival</subject><subject>Receptors, Interleukin-6 - antagonists & inhibitors</subject><subject>Receptors, Interleukin-6 - blood</subject><subject>Receptors, Interleukin-6 - genetics</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVkF1LwzAUhoMobk5_gpI_0JnvNDeClqmDgTLrpYQkTbfq1o6kE_bvbZkbepUDed73cB4ArjEaY8zTW4xkmiBGyTjL5glWCZEInYAh5lwmlAh-2s0HZgAuYvxECDOM2DkYUKIoVYoNwcebD9s1nM4ENBEa-BqaRd3EtnLwoWrWJnz5AE1d9MR8j-RLH8zGb3smN2HhW1jVHb2qTNjBPBjXwszUzod4Cc5Ks4r-6vcdgffHSZ49J7OXp2l2P0scw7hNpGXWei8lF0IJI4mjlqWYpoIhTq1XSBFFuFWFSEvrCookV8yUouQFMaikI3C3791s7doXztdtMCu9CVV3wU43ptL_f-pqqRfNt06VSjubXQHfF7jQxBh8ecxipHvfunepe5e6862x0r3vLnfzd_ExdRBMfwCnxHvm</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Høgdall, Dan</creator><creator>O'Rourke, Colm J</creator><creator>Dehlendorff, Christian</creator><creator>Larsen, Ole F</creator><creator>Jensen, Lars H</creator><creator>Johansen, Astrid Z</creator><creator>Dang, Hien</creator><creator>Factor, Valentina M</creator><creator>Grunnet, Mie</creator><creator>Mau-Sørensen, Morten</creator><creator>Oliveira, Douglas V N P</creator><creator>Linnemann, Dorte</creator><creator>Boisen, Mogens K</creator><creator>Wang, Xin W</creator><creator>Johansen, Julia S</creator><creator>Andersen, Jesper B</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20201101</creationdate><title>Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers</title><author>Høgdall, Dan ; O'Rourke, Colm J ; Dehlendorff, Christian ; Larsen, Ole F ; Jensen, Lars H ; Johansen, Astrid Z ; Dang, Hien ; Factor, Valentina M ; Grunnet, Mie ; Mau-Sørensen, Morten ; Oliveira, Douglas V N P ; Linnemann, Dorte ; Boisen, Mogens K ; Wang, Xin W ; Johansen, Julia S ; Andersen, Jesper B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-7b4bbee7756696a72c3b4813864053be9092925b9d68fbcd307594af6f5d2a0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Animals</topic><topic>Antigens, Tumor-Associated, Carbohydrate - blood</topic><topic>Antigens, Tumor-Associated, Carbohydrate - genetics</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Biliary Tract Neoplasms - blood</topic><topic>Biliary Tract Neoplasms - drug therapy</topic><topic>Biliary Tract Neoplasms - genetics</topic><topic>Biliary Tract Neoplasms - pathology</topic><topic>Biomarkers, Tumor - blood</topic><topic>Cell Proliferation - drug effects</topic><topic>Chitinase-3-Like Protein 1 - blood</topic><topic>Chitinase-3-Like Protein 1 - genetics</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - adverse effects</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Interleukin-6 - blood</topic><topic>Interleukin-6 - genetics</topic><topic>Male</topic><topic>Mice</topic><topic>Middle Aged</topic><topic>Palliative Care</topic><topic>Prognosis</topic><topic>Progression-Free Survival</topic><topic>Receptors, Interleukin-6 - antagonists & inhibitors</topic><topic>Receptors, Interleukin-6 - blood</topic><topic>Receptors, Interleukin-6 - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Høgdall, Dan</creatorcontrib><creatorcontrib>O'Rourke, Colm J</creatorcontrib><creatorcontrib>Dehlendorff, Christian</creatorcontrib><creatorcontrib>Larsen, Ole F</creatorcontrib><creatorcontrib>Jensen, Lars H</creatorcontrib><creatorcontrib>Johansen, Astrid Z</creatorcontrib><creatorcontrib>Dang, Hien</creatorcontrib><creatorcontrib>Factor, Valentina M</creatorcontrib><creatorcontrib>Grunnet, Mie</creatorcontrib><creatorcontrib>Mau-Sørensen, Morten</creatorcontrib><creatorcontrib>Oliveira, Douglas V N P</creatorcontrib><creatorcontrib>Linnemann, Dorte</creatorcontrib><creatorcontrib>Boisen, Mogens K</creatorcontrib><creatorcontrib>Wang, Xin W</creatorcontrib><creatorcontrib>Johansen, Julia S</creatorcontrib><creatorcontrib>Andersen, Jesper B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Høgdall, Dan</au><au>O'Rourke, Colm J</au><au>Dehlendorff, Christian</au><au>Larsen, Ole F</au><au>Jensen, Lars H</au><au>Johansen, Astrid Z</au><au>Dang, Hien</au><au>Factor, Valentina M</au><au>Grunnet, Mie</au><au>Mau-Sørensen, Morten</au><au>Oliveira, Douglas V N P</au><au>Linnemann, Dorte</au><au>Boisen, Mogens K</au><au>Wang, Xin W</au><au>Johansen, Julia S</au><au>Andersen, Jesper B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2020-11-01</date><risdate>2020</risdate><volume>26</volume><issue>21</issue><spage>5655</spage><epage>5667</epage><pages>5655-5667</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><notes>Authors’ Contributions</notes><notes>J.S. Johansen and J.B. Andersen contributed equally to this article.</notes><notes>D. Høgdall: Conceptualization, resources, data curation, formal analysis, supervision, funding acquisition, validation, investigation, visualization, methodology, writing-original draft, project administration, writing-review and editing. C.J. O’Rourke: Conceptualization, resources, data curation, formal analysis, supervision, validation, visualization, methodology, writing-original draft, writing-review and editing. C. Dehlendorff: Data curation, formal analysis, validation, methodology, writing-original draft, writing-review and editing. O.F. Larsen: Conceptualization, data curation, supervision, project administration, writing-review and editing. L.H. Jensen: Resources, data curation, writing-review and editing. A.Z. Johansen: Resources, data curation, formal analysis, writing-original draft, writing-review and editing. H. Dang: Conceptualization, resources, data curation, formal analysis, supervision, project administration, writing-review and editing. V.M. Factor: Data curation, supervision, methodology, project administration, writing-review and editing. M. Grunnet: Resources, data curation, writing-review and editing. M. Mau-Sørensen: Resources, data curation, writing-review and editing. D.V.N.P Oliveira: Resources, writing-review and editing. D. Linnemann: Resources, data curation, formal analysis, supervision, methodology, writing-review and editing. M.K. Boisen: Conceptualization, data curation, supervision, validation, methodology, writing-review and editing. X.W. Wang: Resources, data curation, supervision, methodology, writing-review and editing. J.S. Johansen: Conceptualization, resources, data curation, formal analysis, supervision, funding acquisition, validation, investigation, visualization, methodology, project administration, writing-review and editing. J.B. Andersen: Conceptualization, resources, data curation, formal analysis, supervision, funding acquisition, validation, methodology, project administration, writing-review and editing.</notes><abstract>Biliary tract cancer (BTC) is a heterogeneous group of rare gastrointestinal malignancies with dismal prognosis often associated with inflammation. We assessed the prognostic value of IL6 and YKL-40 compared with CA19-9 before and during palliative chemotherapy. We also investigated in mice whether IL6R inhibition in combination with gemcitabine could prolong chemosensitivity.
A total of 452 Danish participants with advanced (locally advanced and metastatic) BTC were included from six clinical trials (February 2004 to March 2017). Serum CA19-9, IL6, and YKL-40 were measured before and during palliative treatment. Associations between candidate biomarkers and progression-free survival (PFS) and overall survival (OS) were analyzed by univariate and multivariate Cox regression. Effects of inhibiting IL6R and YKL-40 were assessed
, and of IL6R inhibition
.
High pretreatment levels of CA19-9, IL6, and YKL-40, and increasing levels during treatment, were associated with short PFS and OS in patients with advanced BTC. IL6 provided independent prognostic information, independent of tumor location and in patients with normal serum CA19-9. ROC analyses showed that IL6 and YKL-40 were predictive of very short OS (OS < 6 months), whereas CA19-9 was best to predict OS > 1.5 years. Treatment with anti-IL6R and gemcitabine significantly diminished tumor growth when compared with gemcitabine monotherapy in an
transplant model of BTC.
Serum IL6 and YKL-40 are potential new prognostic biomarkers in BTC. IL6 provides independent prognostic information and may be superior to CA19-9 in certain contexts. Moreover, anti-IL6R should be considered as a new treatment option to sustain gemcitabine response in patients with BTC.</abstract><cop>United States</cop><pmid>32933994</pmid><doi>10.1158/1078-0432.CCR-19-2700</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2020-11, Vol.26 (21), p.5655-5667 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8998158 |
| source | Freely Accessible Science Journals |
| subjects | Adult Aged Aged, 80 and over Animals Antigens, Tumor-Associated, Carbohydrate - blood Antigens, Tumor-Associated, Carbohydrate - genetics Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Biliary Tract Neoplasms - blood Biliary Tract Neoplasms - drug therapy Biliary Tract Neoplasms - genetics Biliary Tract Neoplasms - pathology Biomarkers, Tumor - blood Cell Proliferation - drug effects Chitinase-3-Like Protein 1 - blood Chitinase-3-Like Protein 1 - genetics Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Disease-Free Survival Female Humans Interleukin-6 - blood Interleukin-6 - genetics Male Mice Middle Aged Palliative Care Prognosis Progression-Free Survival Receptors, Interleukin-6 - antagonists & inhibitors Receptors, Interleukin-6 - blood Receptors, Interleukin-6 - genetics |
| title | Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T15%3A25%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20IL6%20as%20a%20Prognostic%20Biomarker%20and%20IL6R%20as%20a%20Therapeutic%20Target%20in%20Biliary%20Tract%20Cancers&rft.jtitle=Clinical%20cancer%20research&rft.au=H%C3%B8gdall,%20Dan&rft.date=2020-11-01&rft.volume=26&rft.issue=21&rft.spage=5655&rft.epage=5667&rft.pages=5655-5667&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-19-2700&rft_dat=%3Cpubmed_cross%3E32933994%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c411t-7b4bbee7756696a72c3b4813864053be9092925b9d68fbcd307594af6f5d2a0f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/32933994&rfr_iscdi=true |